Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

PURPOSE: Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer eventually develop resistance to dual-antibody therapy with trastuzumab plus pertuzumab. Mechanisms of resistance have not been well elucidated. We evaluated the safety, tolerability, and efficac...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Abraham, Jame, Montero, Albert J., Jankowitz, Rachel C., Salkeni, Mohamad Adham, Beumer, Jan H., Kiesel, Brian F., Piette, Fanny, Adamson, Laura M., Nagy, Rebecca J., Lanman, Richard B., Sperinde, Jeff, Huang, Weidong, Allegra, Carmen J., Srinivasan, Ashok, Wang, Ying, Pogue-Geile, Katherine L., Lucas, Peter C., Jacobs, Samuel A.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2019
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784849/
https://ncbi.nlm.nih.gov/pubmed/31442103
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00858
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki